June 1, 2017 Bio/Pharma/CRO Clinical Research/Diagn.

Announcement on submission of the Clinical Trial Plan Notification for phase I clinical trial of Oncolytic virus HF10 against pancreatic cancer in Japan

2017 2017/06/01 Announcement on submission of the Clinical Trial Plan Notification for phase I clinical trial of Oncolytic virus HF10 against pancreatic cancer in Japan Kusatsu/Shiga, Japan — Jun 1, 2017 — Takara Bio Inc. (Takara Bio) announced that the Clinical Trial Notification was submitted to PMDA (Pharmaceuticals and Medical Devices Agency; Japanese regulatory agency)... Read more

June 1, 2017 Clinical Research/Diagn. Lab Top-10 M&A, Partnerships

Philips and Illumina team up with Navican, an Intermountain Healthcare Company, to Accelerate the Delivery of Precision Medicine to Health Systems Worldwide

– New “turnkey” approach to precision medicine seeks to deliver Intermountain’s best practices into a streamlined service to be integrated at the point of care – Solution’s goal is to benefit late stage cancer patients through advanced analytics and expert decision support, combined with providing better access to targeted treatments and clinical trials NEWS PROVIDED... Read more

May 29, 2017 Bio/Pharma/CRO Clinical Research/Diagn.

First patient enrolled into Oncolytic Virus HF10 phase II clinical trial in Japan

2017 2017/05/29 First patient enrolled into Oncolytic Virus HF10 phase II clinical trial in Japan Kusatsu/Shiga, Japan — May 29, 2017 — Takara Bio Inc. (Takara Bio), today announced that the first patient with melanoma has been enrolled into Oncolytic Virus HF10(TBI-1401) phase II clinical trial in Japan on May 26, 2017. In this clinical study,... Read more

May 25, 2017 Clinical Research/Diagn. PR/Corporate

Luminex Corporation To Present At Jefferies 2017 Global Healthcare Conference

AUSTIN, Texas, May 25, 2017 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) announced today that management will present at the Jefferies 2017 Global Healthcare Conference on Thursday, June 8 at 8:30am ET in New York. The investor presentation will be webcast live and may be accessed at Luminex Corporation’s website at http://www.luminexcorp.com. Simply log on to the web at... Read more

May 24, 2017 Clinical Research/Diagn. Mass Spectrometry Product Launch

SCIEX Announces the First FDA-Cleared Vitamin D Assay Kit for Mass Spectrometry

SCIEX Vitamin D 200M Assay for the TopazTM System designed to measure Vitamin D with greater accuracy and simplicity for In Vitro Diagnostic (IVD) analysis in clinical diagnostic labs May 24, 2017 Framingham, MA — SCIEX Diagnostics, the in vitro diagnostics division of SCIEX, a global leader in mass spectrometry in the life sciences industry,... Read more

May 23, 2017 Clinical Research/Diagn. Lab Top-10 M&A, Partnerships

Seegene enters the U.S. diagnostic market in collaboration with Thermo Fisher Scientific

PR Newswire 2017.05.22 Seoul, Korea, 2017/05/22 – Seegene Inc. (096530.KQ), the world’s leading developer of multiplex molecular diagnostics technologies and assays, today announced that it has entered into a new strategic collaboration relationship with Thermo Fisher Scientific in which Seegene will file for U.S Food and Drug Administration (FDA) clearance of its AllplexTM diagnostic assay... Read more

May 23, 2017 Cell Analysis Tools Clinical Research/Diagn. Microscopy Product Launch

Find the Missing Links in Advanced Live Cell Research – Leica launches DMi8 S live cell imaging solution

The DMi8 S with LASX Navigator allows researchers to quickly create high resolution overviews like the whole mouse brain in this example. This facilitates orientation on the sample and easy discovery of critical regions for further examination. Image courtesy of Dr. Wei Mo, School of Life Sciences, Xiamen University, China. “Live-cell imaging is the future... Read more

May 23, 2017 Acad, Gov/Utilities Clinical Research/Diagn.

FDA approves Roche’s Actemra/RoActemra (tocilizumab) for giant cell arteritis

Basel, 23 May 2017 FDA approves Roche’s Actemra/RoActemra (tocilizumab) for giant cell arteritis Actemra/RoActemra is the first FDA-approved treatment for adults with giant cell arteritis (GCA) FDA previously granted Priority Review and Breakthrough Therapy Designation for Actemra/RoActemra in GCA Sixth FDA approval for Actemra/RoActemra since its US launch in 2010 Roche (SIX: RO, ROG; OTCQX:... Read more